Your browser doesn't support javascript.
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar.
Zaqout, Ahmed; Almaslamani, Muna A; Chemaitelly, Hiam; Hashim, Samar A; Ittaman, Ajithkumar; Alimam, Abeir; Rustom, Fatma; Daghfal, Joanne; Abukhattab, Mohammed; AlMukdad, Sawsan; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Butt, Adeel A; Bertollini, Roberto; Al-Khal, Abdullatif; Omrani, Ali S; Abu-Raddad, Laith J.
  • Zaqout A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar. Electronic address: azaqout@hamad.qa.
  • Almaslamani MA; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Chemaitelly H; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Cornell Universit
  • Hashim SA; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Ittaman A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Alimam A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Rustom F; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Daghfal J; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
  • Abukhattab M; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • AlMukdad S; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Cornell Universit
  • Kaleeckal AH; Hamad Medical Corporation, Doha, Qatar.
  • Latif AN; Hamad Medical Corporation, Doha, Qatar.
  • Butt AA; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, United States; Department of Medicine, Weill Cornell Medicine, New York, United States and Doha, Qatar.
  • Bertollini R; Ministry of Public Health, Doha, Qatar.
  • Al-Khal A; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Omrani AS; Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Faculty of Medicine, Qatar University, Doha, Qatar.
  • Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine - Qatar, Cornell Universit
Int J Infect Dis ; 124: 96-103, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2031346
ABSTRACT

OBJECTIVES:

To estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant.

METHODS:

We conducted a matched case-control study among all individuals eligible for sotrovimab treatment per United States Food and Drug Administration guidelines in the resident population of Qatar. The odds of progression to severe forms of COVID-19 were compared in cases (treatment group) versus controls (eligible patients who opted not to receive the treatment). Subgroup analyses were conducted.

RESULTS:

A total of 3364 individuals were eligible for sotrovimab treatment during the study period, of whom 519 individuals received the treatment, whereas the remaining 2845 constituted the controls. The adjusted odds ratio of disease progression to severe, critical, or fatal COVID-19 comparing the treatment group to the control group was 2.67 (95% confidence interval 0.60-11.91). In the analysis including only the subgroup of patients at higher risk of severe forms of COVID-19, the adjusted odds ratio was 0.65 (95% confidence interval 0.17-2.48).

CONCLUSION:

There was no evidence for a protective effect of sotrovimab in reducing COVID-19 severity in a setting dominated by the BA.2 subvariant.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article